The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
A Brief History of Anti-VEGF for the Treatment of Ocular Angiogenesis
Open accessAbstract
In 1994, The American Journal of Pathology published a key article reporting that hypoxic retina produces vascular endothelial growth factor (VEGF), suggesting a role for VEGF in ocular neovascularization. Subsequent developments in anti-VEGF treatment for neovascular eye disease have improved visual outcomes and changed the standard of care in retinal medicine and ophthalmology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
VEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691 · cited 2×
“Another anti-VEGF strategy, developed by Regeneron Pharmaceuticals (Tarrytown, NY), consists of a chimeric fusion protein comprising the second immunoglobulin domain of VEGF receptor 1, the third immunoglobulin domain of VEGF receptor 2, and the Fc portion of human IgG1.(26) This so-called VEGF-trap (aflibercept) func…”
Background
Cited by
Taylor, D. J., Hobby, A. E., Binns, A. M., & Crabb, D. P. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-011504 · Cited by 288
Bongiovì, F., Fiorica, C., Palumbo, F. S., Di Prima, G., Giammona, G., & Pitarresi, G. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00620 · Cited by 44
Nanoparticle-Mediated Expression of a Wnt Pathway Inhibitor Ameliorates Ocular Neovascularization
Wang, Z., Cheng, R., Lee, K., Tyagi, P., Ding, L., Kompella, U. B., Chen, J., Xu, X., & Ma, J.-X. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.114.304627 · Cited by 38
Lee, S., Kang, I. K., Kim, J. H., Jung, B. K., Park, K., Chang, H., Lee, J. Y., & Lee, H. (2019) · Translational Vision Science & Technology · doi:10.1167/tvst.8.2.14 · Cited by 27
Gene-based therapeutics for acquired retinal disease: opportunities and progress
Tan, T.-E., Fenner, B. J., Barathi, V. A., Tun, S. B. B., Wey, Y. S., Tsai, A. S. H., Su, X., Lee, S. Y., Cheung, C. M. G., Wong, T. Y., et al. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.795010 · Cited by 26
Metadata
- Authors
- Kim, L. A., & D'Amore, P. A.
- Venue
- The American Journal of Pathology
- Publisher
- Elsevier BV
- Published
- 2012-08
- Volume
- 181
- Issue
- 2
- Pages
- 376-379
- ISSN
- 0002-9440 (ISSN-L)
- OpenAlex
- W2042978638
- Cited by
- 220
- References
- 7
- FWCI
- 6.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Brief History of Anti-VEGF for the Treatment of Ocular Angiogenesis. https://app.cochat.ai/papers/10.1016/j.ajpath.2012.06.006
- The paper
- Kim, L. A., & D'Amore, P. A. (2012). A Brief History of Anti-VEGF for the Treatment of Ocular Angiogenesis. The American Journal of Pathology. https://doi.org/10.1016/j.ajpath.2012.06.006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.